3Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev, 1997, 61:377-392
4Ince D, Zhang X, Silver L C, et al. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother, 2002, 46(11): 3370～3380
5Ince D, Hooper DC. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother, 2001, 45(10):2755-2764
6Hartman-Neumann S, DenBleyker K, Pelosi L A, et al. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756. Antimicrob Agents Chemother, 2001, 45(10):2865～2870
7Jorgensen J H, Weigel L M, Ferraro M J, et al. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.Antimicrob Agents Chemother, 1999, 43(2):329～334
8Oto M, Miyake S, Yuasa Y. Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresisapparatus. Anal Biochem, 1993, 213(1): 19-22
9Bassam B J, Caetano-Anolles G, Gresshoff P M. Fastand sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem, 1991, 196(1):80-83
10Chu Y W, Houang E T, Lyon D J, et al. Antimicrobial resistance in Shigella flexneri and Shigella sonnei in Hong Kong, 1986 to 1995. Antimicrob AgentsChemother, 1998, 42(2):440-443
